Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Teaching an Old Molecule New Tricks: Drug Repositioning for Duchenne Muscular Dystrophy
Libero Vitiello, Lucia Tibaudo, Elena Pegoraro, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 23, pp. 6053-6053
Open Access | Times Cited: 18

Showing 18 citing articles:

Antibiotics from rare actinomycetes, beyond the genus Streptomyces
Jonathan Parra, Ainsley Beaton, Ryan F. Seipke, et al.
Current Opinion in Microbiology (2023) Vol. 76, pp. 102385-102385
Open Access | Times Cited: 31
Current Pharmacological Strategies for Duchenne Muscular Dystrophy
Shanshan Yao, Zihao Chen, Liang Yu, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 48
Metformin Reverses the Enhanced Myocardial SR/ER–Mitochondria Interaction and Impaired Complex I-Driven Respiration in Dystrophin-Deficient Mice
Claire Angebault, Mathieu Panel, M. Lacôte, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 8
Open Access | Times Cited: 34
A Brief Review of Duchenne Muscular Dystrophy Treatment Options, with an Emphasis on Two Novel Strategies
Ahlke Heydemann, Maria Siemionow
Biomedicines (2023) Vol. 11, Iss. 3, pp. 830-830
Open Access | Times Cited: 13
Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy
John Bourke, Teofila Bueser, Rosaline C. M. Quinlivan
Cochrane library (2018) Vol. 2020, Iss. 2
Open Access | Times Cited: 44
Repurposing Antiepileptic Drugs for Cancer: A Promising Therapeutic Strategy
Noor Tarawneh, S. A. Hussein, Shtaywy Abdalla
Journal of Clinical Medicine (2025) Vol. 14, Iss. 8, pp. 2673-2673
Open Access
Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies
Ilaria Andreana, Mathieu Repellin, Flavia Carton, et al.
Pharmaceutics (2021) Vol. 13, Iss. 2, pp. 278-278
Open Access | Times Cited: 21
Restoring susceptibility to aminoglycosides: identifying small molecule inhibitors of enzymatic inactivation
Angel J. Magaña, Jan Sklenicka, Clemencia Pinilla, et al.
RSC Medicinal Chemistry (2023) Vol. 14, Iss. 9, pp. 1591-1602
Closed Access | Times Cited: 8
Kanamycin and Cisplatin Ototoxicity: Differences in Patterns of Oxidative Stress, Antioxidant Enzyme Expression and Hair Cell Loss in the Cochlea
Alejandro Gibaja, Juan Carlos Alvarado, Verena Scheper, et al.
Antioxidants (2022) Vol. 11, Iss. 9, pp. 1759-1759
Open Access | Times Cited: 10
Aberrant NLRP3 Inflammasome Activation Ignites the Fire of Inflammation in Neuromuscular Diseases
Christine Péladeau, Jagdeep K. Sandhu
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 6068-6068
Open Access | Times Cited: 14
A Novel MAO-B/SSAO Inhibitor Improves Multiple Aspects of Dystrophic Phenotype in mdx Mice
Francesca Gasparella, Leonardo Nogara, Elena Germinario, et al.
Antioxidants (2024) Vol. 13, Iss. 6, pp. 622-622
Open Access | Times Cited: 1
Pharmacological Treatments and Therapeutic Targets in Muscle Dystrophies Generated by Alterations in Dystrophin-Associated Proteins
Alexandra Luna‐Angulo, Carlos Landa‐Solís, Rosa Elena Escobar‐Cedillo, et al.
Medicina (2024) Vol. 60, Iss. 7, pp. 1060-1060
Open Access | Times Cited: 1
A state-of-the-art review of tamoxifen as a potential therapeutic for duchenne muscular dystrophy
Valeria Botti, Olivier Menzel, Davide Staedler
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 7
2-(3,4-Dihydroxyphenyl)-4-(2-(4-nitrophenyl)hydrazono)-4H-chromene-3,5,7-triol
Alessandra Gianoncelli, Alberto Ongaro, Giuseppe Zagotto, et al.
Molbank (2020) Vol. 2020, Iss. 3, pp. M1144-M1144
Open Access | Times Cited: 8
Vascular therapy for Duchenne muscular dystrophy (DMD)
Sangharsha Thapa, Shaymaa Elhadidy, Atsushi Asakura
Faculty Reviews (2023) Vol. 12
Open Access | Times Cited: 2
Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy
Shalini M Krishnan, Johannes Nordlohne, Lisa Dietz, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 8016-8016
Open Access | Times Cited: 3
Elucidation of bioinformatic-guided high-prospect drug repositioning candidates for DMD via Swanson linking of target-focused latent knowledge from text-mined categorical metadata
J. Wes Ulm, Florian Barthélémy, Stanley F. Nelson
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access
A retooled drug that restores ionic balance and cardiac function in dystrophin deficient hearts
Ryan D. Wuebbles, Dean J. Burkin
International Journal of Cardiology (2020) Vol. 319, pp. 115-116
Closed Access
Page 1

Scroll to top